We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Color-Coded Microspheres Make Vessel Embolization Easier

By HospiMedica International staff writers
Posted on 13 Jan 2009
Syringes that are pre-filled with a range of color-coded embolization microspheres enable physicians to accurately perform blood vessel occlusions.

The Embozene Color-Advanced microspheres are intended for treatment of hyper-vascularized tumors such as uterine fibroids, ArterioVenous Malformations (AVMs), hepatocellular carcinomas (HCCs), and other highly vascularized cancers. More...
The microspheres consist of a hydrogel core and an exterior shell made from Polyzene-F (poly[bis(trifluroexthoxy)phosphazene]), and are color- enhanced with a different color for each size for increased procedural safety, efficiency, and visibility. The microspheres are available in 40 micrometers, 100 micrometers, 250 micrometers, 400 micrometers, 500 micrometers, 700 micrometers, and 900 micrometers sizes, in both 1 ml and 2 ml pre-filled syringes and vials. The microspheres are precisely calibrated and retain their shape after passing through a catheter, allowing them to stay in the delivery suspension for an extended period.

The color-coding improves particle visibility, increases procedural safety, and optimizes handling and convenience for the physician. Instant visual confirmation of the microsphere size eliminates potential waste due to size uncertainty, when operating with multiple microsphere sizes. Using different containers prevents contamination of saline and contrast syringes during the procedure. The increased visibility allows confirmation of microsphere levels in the suspension prior to and during injection, and reduces the risk of injecting too many or very few particles because the microspheres are visible, especially when using smaller sizes. The Embozene Color-Advanced microspheres are a product of CeloNova BioSciences (Newnan, GA, USA), and have been approved by both the U.S. Food and Drug Administration (FDA) and the European Community (CE Marking).

"From the outset, we took a different approach to developing our Embozene Microspheres by asking physicians and medical scientists for the qualities and characteristics that the ideal embolic device should have,” said Thomas A. Gordy, President and CEO of CeloNova BioSciences. "Then we engineered Embozene Microspheres to have those properties, which are made even better with Polyzene-F, our proprietary polymer.”

Related Links:
CeloNova BioSciences




Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Absorbable Monofilament Mesh
Phasix Mesh
Gas Consumption Analyzer
Anesthetic Gas Consumption Analyzer
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.